Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BBOX1 | O75936 | 8/20 | 0.56 |
| ▸ | ACHE | P22303 | 3/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | APEX1 | P27695 | 3/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.47 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL233637 | 0.92 | BBOX1 (0.64) | BBOX1ACHECA1MEN1KMT2A | |
| Hexanoate SCHEMBL5574422 | 0.91 | CA1 (0.58) | BBOX1CA1 | |
| Hydrochloric Acid SCHEMBL25181735 | 0.90 | BBOX1 (0.61) | BBOX1ACHECA1MEN1KMT2A | |
| Decanoic Acid SCHEMBL5573520 | 0.89 | DNM1 (0.60) | CA1 | |
| Decanoic Acid SCHEMBL5573560 | 0.89 | DNM1 (0.60) | CA1 | |
| Adipic Acid SCHEMBL17435040 | 0.89 | DNM1 (0.60) | CA1 | |
| Adipic Acid SCHEMBL8163652 | 0.89 | DNM1 (0.60) | CA1 | |
| Stearic Acid SCHEMBL4942597 | 0.89 | DNM1 (0.60) | CA1 | |
| Octanoic Acid SCHEMBL5574961 | 0.89 | DNM1 (0.60) | CA1 | |
| Decanoic Acid SCHEMBL5573592 | 0.89 | DNM1 (0.60) | CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260002950-A1 | Uses of 5-Aminovaleric Acid Betaine and Compositions Related Thereto | UNIV EMORY (US) | 2026-01-01 | — | — | US | disclosed |
| US-20230384327-A1 | GUT MICROBIOTA-RELATED METHODS FOR TREATING DEMENTIA AND AGE-DEPENDENT COGNITIVE DECLINE | ALBERT-LUDWIGS-UNIVERSITAT FREIBURG (DE) | 2023-11-30 | — | — | US | disclosed |
| US-20230384327-A1 | GUT MICROBIOTA-RELATED METHODS FOR TREATING DEMENTIA AND AGE-DEPENDENT COGNITIVE DECLINE | ALBERT-LUDWIGS-UNIVERSITAT FREIBURG (DE) | 2023-11-30 | — | — | US | disclosed |
| US-20230072788-A1 | Uses of 5-Aminovaleric Acid Betaine and Compositions Related Thereto | UNIV EMORY (US) | 2023-03-09 | — | — | US | disclosed |
| EP-4081804-A1 | GUT MICROBIOTA-RELATED METHODS FOR TREATING DEMENTIA AND AGE-DEPENDENT COGNITIVE DECLINE | Albert-Ludwigs-Universität Freiburg (DE) | 2022-11-02 | — | — | EP | disclosed |
| EP-3879272-A1 | GUT MICROBIOTA-RELATED METHODS FOR TREATING DEMENTIA AND AGE-DEPENDENT COGNITIVE DECLINE | Albert-Ludwigs-Universität Freiburg (DE) | 2021-09-15 | — | — | EP | disclosed |
| WO-2021130267-A1 | GUT MICROBIOTA-RELATED METHODS FOR TREATING DEMENTIA AND AGE-DEPENDENT COGNITIVE DECLINE | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2021-07-01 | — | — | WO | disclosed |
| US-20130005806-A1 | ANALYSIS OF TMLHE AND CARNITINE BIOSYNTHESIS FOR AUTISM DIAGNOSIS | BEAUDET ARTHUR L (US) | 2013-01-03 | — | — | US | disclosed |
| CN-102781922-A | TGR5 agonists | EXELIXIS INC | 2012-11-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260002950-A1 | Uses of 5-Aminovaleric Acid Betaine and Compositions Related Thereto | CPT1B, SLC10A2, TNNT2 | BBOX1 165/4885ACHE 464/4885CA1 1109/4885 |
| US-20130005806-A1 | ANALYSIS OF TMLHE AND CARNITINE BIOSYNTHESIS FOR AUTISM DIAGNOSIS | SLC25A20, CRAT, BHMT | BBOX1 40/4885ACHE 2316/4885CA1 1280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.